LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction. The therapies are designed to reduce or prevent […]
Read more →After 10 years, Dr. Holtz has stepped away from CEO and managerial duties at InterveXion to focus on ventures and technologies in pharmaceutical production.
Read more →The company is pleased to report publication of the results of the first human study of ch-mAb7F9. The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an anti-methamphetamine monoclonal antibody, in healthy volunteers. […]
Read more →InterveXion and UAMS have published a new manuscript describing the effects of two monoclonal antibodies designed to treat METH abuse. The studies compare the two antibodies and describe the factors that resulted in the choice of mAb7F9 for clinical development. Abstract – This lead candidate selection study […]
Read more →A new manuscript published by UAMS describes the shortened duration of repeated METH dose effects in rats over a month following administration of mAb7F9. Abstract – This study assessed clinical scenarios of continuing monoclonal antibody (mAb) treatment for (+)- methamphetamine (METH) addiction, and the implications of missing […]
Read more →InterveXion and UAMS have published a new manuscript describing the development of the ch-mAb7F9 antibody and early studies demonstrating it’s bioequivalence to the murine mAb7F9. Abstract - Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a […]
Read more →InterveXion has been granted a meeting with FDA in January 2014 to discuss the development program for ch-mAb7F9. The purpose of the meeting is three-fold: 1) to discuss the results of the Phase 1a study, 2) to confirm that the proposed nonclinical studies will support a Phase […]
Read more →InterveXion Therapeutics reports that all subjects have completed all planned follow-up appointments in the first clinical study of ch-mAb7F9, the company’s first investigational anti-methamphetamine antibody product. Forty-two (42) non-METH using volunteer subjects were dosed with antibody or placebo in the study starting in May 2012. Because of […]
Read more →LITTLE ROCK – InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions. The medication is expected to significantly reduce or prevent the euphoric rush […]
Read more →Chief Scientific Officer, Mike Owens, Ph.D., was quoted in the Wall Street Journal discussing the potential of anti-methamphetamine antibodies to be available in the right amount at the right time. Read the essay…
Read more →